BGMS
NASDAQ · Biotechnology
Bio Green Med Solution Inc
$0.84
+0.11 (+15.71%)
BGMS News30 articles
Bio Green Med Stock Surges 170% Pre-Market on All-Stock Future NRG Deal, Massive Dilution Ahead
Bio Green Med shares soared nearly 170% pre-market on an all-stock deal to buy Future NRG, but existing holders will own under 1% of the combined firm, raising dilution concerns.
Generate Biomedicines Shares Reclaim IPO Price After Heavy Trading Week
Generate Biomedicines (GENB) surged 13.7% in a week, closing Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as sector momentum lifts biotech stocks.
ImmunityBio Volume Surges on Russell Index Changes; Monday Trading Key
ImmunityBio surged 11.8% on Friday with volume tripling its average, driven by Russell index reconstitution. Monday's trading will reveal if the spike holds.
ImmunityBio Jumps on Russell Index Rebalancing and High Valuation
ImmunityBio surged 9.2% to $8.51 as its market cap exceeded the Russell 1000 cutoff, drawing buyers ahead of index reconstitution.
Can-Fite BioPharma Surges on Japanese Patent Grant for Obesity Drug
Can-Fite BioPharma shares surged 17% premarket after Japan allowed a patent for Namodenoson in obesity, but the company's $6.61M market cap remains near the NYSE American delisting threshold.
Bio-Techne Jumps on Merck KGaA Cash Bid; Spread Signals Deal Risk
Bio-Techne shares jumped 19% on Merck KGaA's $73 cash offer, leaving a $2.83 spread as the deal awaits shareholder and regulatory approvals.
Iovance Biotherapeutics Stock Surges on $89.7 Million ATM Offering
Iovance shares rose 9.4% after launching an $89.65 million ATM stock sale, as investors balance dilution risks against the potential for accelerated Amtagvi revenue growth.
Landseed Secures $400K to Advance Sensor-Based Biodiversity Verification
Landseed raised $400,000 to develop AI sensors that verify ecological outcomes for biodiversity credits, targeting market trust issues.
Lunai Bioworks Shares Surge on Nasdaq Compliance Filing
Lunai Bioworks shares surged 80.88% after hours to $5.15 after Nasdaq confirmed compliance with the $1 minimum bid-price rule, averting delisting risk, though the company remains under a one-year panel monitor and has expressed substantial doubt about its ability to continue operations.
Regentis Biomaterials Shares Retreat After Record Surge on Withdrawal of Share Offering
Regentis Biomaterials shares dropped 27.66% premarket after a 506% surge driven by the withdrawal of a planned share offering, with investors focusing on upcoming surgeon training and funding concerns.
Theriva Biologics Surges on Phase 1 Cancer Data, But Risks Remain
TOVX surged 74.6% on Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump is not based on approval or revenue.
Propanc Biopharma Soars After Announcing $5M Stock Buyback
Propanc Biopharma shares skyrocketed after the company authorized a $5 million stock buyback, surpassing its entire market value. Investors now watch for progress on its cancer drug PRP.
Regentis Biomaterials Stock: Surgeon Training for GelrinC Knee Implant Set for Q3
Regentis Biomaterials shares fell slightly premarket after announcing European surgeon training for its GelrinC knee implant will start in Q3, a commercial milestone but not yet revenue.
BioCardia Surges on FDA Minutes Showing CardiAMP Trial Can Support PMA
BioCardia shares surged 52% to $1.40 after FDA meeting minutes confirmed its CardiAMP HF II trial may support a PMA for heart-failure cell therapy, bucking a weak biotech sector.
Legend Biotech Surges 42% on Promising Early CAR-T Data
Legend Biotech shares surged 42% after early Phase 1 data showed all six high-dose patients with relapsed B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy, with five achieving complete responses.
Legend Biotech Surges on Promising Early In Vivo CAR-T Data
Legend Biotech shares soared over 35% after early Phase 1 data showed all six high-dose patients with relapsed/refractory B-cell NHL responded to its in vivo CAR-T drug LB2501, with five complete responses and no relapses as of April 1.
Artelo Biosciences Shares Swing Wildly After Shelf Filing
Artelo Biosciences shares plunged 10.5% to a 52-week low of $1.19 before rebounding to $2.01 in after-hours trading, driven by capital market moves and early-stage pipeline updates.
Apellis Delisted After Biogen's $5.3B Acquisition Closes
Biogen closed its $5.3 billion acquisition of Apellis, ending APLS trading on Nasdaq. Shareholders got $41 per share plus a CVR linked to Syfovre sales milestones.
HCW Biologics Rockets 122% as Traders Flock to Micro-Cap Biotech
HCW Biologics shares skyrocketed 122% to $2.35 on Wednesday as traders piled into the micro-cap biotech, fueled by a new stock offering and first-quarter revenue of $6.54 million from a licensing deal.
Biogen Closes Apellis Takeover; Focus Shifts to Syfovre Milestones
Biogen has completed its $5.6 billion acquisition of Apellis Pharmaceuticals, delisting APLS from Nasdaq. Shareholders received $41 per share plus a contingent value right linked to Syfovre sales targets.
ImmunityBio's Anktiva Expansion Faces FDA Scrutiny with 2027 Decision Date
ImmunityBio's supplemental BLA for Anktiva in papillary-only bladder cancer has been accepted by the FDA, with a decision expected by Jan. 6, 2027. The company's stock traded at $7.76, down 2.8%.
Virax Biolabs Stock Extends Surge on RedChip Promo, Filing
Virax Biolabs shares surged 53.1% Monday and climbed another 17.1% premarket Tuesday, driven by a paid RedChip TV segment and a May 15 ownership filing showing Armistice Capital's 4.99% stake.
GeoVax Shares Surge on Biodefense Funding and Ebola Alert
GeoVax Labs shares surged nearly 80% after announcing a $3 million private placement, riding a wave of biodefense interest sparked by WHO's Ebola emergency in Africa.
Sunshine Biopharma Shares Swing Wildly After $6M Offering
Sunshine Biopharma shares experienced extreme volatility Monday after a $6M public offering, surging 516% before closing up 78% at $0.51.
Apellis Delisted After Biogen Buyout; CVR Payout in Focus
Apellis Pharmaceuticals has been delisted from Nasdaq following Biogen's completed acquisition. Shareholders get $41 per share plus a contingent value right worth up to $4 if Syfovre meets sales goals.
ImmunityBio Secures Patents and BCG Supply Deal for Bladder Cancer Therapy
ImmunityBio announced five U.S. patents protecting its Anktiva-plus-BCG bladder cancer therapy through 2035, and an exclusive supply deal for the Tokyo-172 BCG strain.
Virax Biolabs Surges on TV Segment and Ownership Filing
Virax Biolabs shares surged over 125% in pre-market trading Monday after a sponsored TV segment featuring its CEO and a new SEC filing revealed Armistice Capital holds a 4.99% stake.
Sunshine Biopharma Rebounds Premarket After Dilution Fears
Sunshine Biopharma shares jumped 147% in premarket trading Monday after Friday's steep fall, as traders reacted to a $6 million share-and-warrant registration and a quarterly net loss.
Biogen Closes Apellis Takeover; CVR Offers Upside
Biogen completed its $41/share cash acquisition of Apellis, delisting the stock from Nasdaq. Shareholders also received a contingent value right that could pay up to $4 if Syfovre sales hit targets.
ImmunityBio Secures Exclusive US Rights to Japan BCG Strain for Bladder Cancer
ImmunityBio announced exclusive U.S. rights to Japan BCG Laboratory's Tokyo-172 BCG strain for bladder cancer therapy, with FDA discussions planned. Shares closed at $7.97 Friday, down 2.2%.